IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy [0.03%]
一种新型的抗PD-L1/VEGF双特异性抗体IMM2510用于癌症免疫治疗
Dianze Chen,Zhuli Wu,Xiwen Zhao et al.
Dianze Chen et al.
Background: Dual inhibition of PD-1/PD-L1 and VEGF/VEGFR pathways is a promising strategy to overcome tumor immune evasion and inhibit angiogenesis. IMM2510 is a novel PD-L1 × VEGF bispecific antibody, constructed by fus...
A novel bispecific antibody targeting OX40L and TNFα for the targeted treatment of rheumatoid arthritis [0.03%]
一种针对OX40L和TNFα的双特异性抗体用于靶向治疗类风湿性关节炎
Qun Zhang,Shuliang Song
Qun Zhang
Background: Rheumatoid arthritis is driven by T cell dysregulation and TNFα-mediated inflammation. Dual targeting of OX40 ligand (OX40L) and tumor necrosis factor alpha (TNFα) may offer synergistic therapeutic effects. ...
Correction to: CAR NK cell therapy for solid tumors: potential and challenges [0.03%]
固體腫瘤的CAR-NK細胞治療：潛力和挑戰（補遺）
[This corrects the article DOI: 10.1093/abt/tbaf019.]. Published by Oxford University Press on behalf of the Chinese Antibody Society 2026.
Published Erratum
Antibody therapeutics. 2026 Feb 2;9(1):100. DOI:10.1093/abt/tbag004 2026
A glycoengineered anti-ROR1 antibody, GE-zilovertamab, selectively enhances antibody-dependent cellular cytotoxicity against chronic lymphocytic leukemia [0.03%]
一种甘露糖基化的抗ROR1抗体GE-zilovertamab可增强对慢性淋巴细胞白血病的抗体依赖性细胞毒性作用
Md Kamrul Hasan,George Widhopf Ii,Thomas J Kipps
Md Kamrul Hasan
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is selectively expressed on chronic lymphocytic leukemia (CLL) B cells and certain cancers, but is absent from normal B cells and healthy adult tissues. GE-zilovertamab, an afucosylated...
Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy [0.03%]
双特异性和多特异性T细胞接头分子：推动免疫治疗的未来进展
Xiaoqiang Kang,Yue Zhao,Hong Ling et al.
Xiaoqiang Kang et al.
T-cell engagers (TCEs) represent an emerging class of immunotherapies that harness T cells' cytotoxic power to eliminate diseased cells-a transformative future therapeutic strategy. TCEs form immunological synapses to trigger potent immune ...
The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity [0.03%]
通过整合活性降低的IL-15变异体来增强抗肿瘤活性的下一代NK细胞衔接平台的发展
Lijun Wang,Yinhui Ding,Huifeng Lv et al.
Lijun Wang et al.
Background: Natural killer cell engager (NKCE) has gained attention recently. Conventional NKCEs exhibit mild anti-tumor efficacy despite acceptable safety profiles. Therefore, next-generation NKCE development is essentia...
RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy [0.03%]
靶向癌症治疗的人源化单克隆抗体RO4：针对间皮素膜附近区域的高亲和力抗体
Masanori Onda,Xiufen Liu,Wenlong Liu et al.
Masanori Onda et al.
Background: Mesothelin (MSLN) is a surface antigen highly expressed in several solid tumors, including mesothelioma, ovarian, and pancreatic cancers. However, therapeutic efficacy of MSLN-targeted agents is often compromi...
Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study [0.03%]
针对复发/难治性弥漫大B细胞淋巴瘤患者的独特环状结构CD19/CD22双特异性CAR-T细胞疗法：一项观察性研究
Shuhong Li,Liqiong Liu,Zelin Liu et al.
Shuhong Li et al.
Background: Although CD19 and CD22 chimeric antigen receptor (CAR-T) cell therapies have demonstrated encouraging clinical responses in patients with B-cell lymphoma, over 50% of patients ultimately experience disease pro...
Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodies [0.03%]
近年肿瘤抗原mesothelin结构及与治疗性抗体相互作用研究进展
Jingyu Zhan,Mitchell Ho,Lothar Esser et al.
Jingyu Zhan et al.
The tumor-associated antigen mesothelin is highly expressed in many human cancers, while its expression in normal tissues is limited. Its interaction with the cancer antigen 125 promotes heterotypic cell adhesion and tumor metastasis. Mesot...
Integrative and Emerging Models in Antibody Research: A Comprehensive Review [0.03%]
抗体研究中的综合与新兴模型：全面综述
Jagadeeswara Reddy Devasani,Girijasankar Guntuku,Prathyusha Sarabu et al.
Jagadeeswara Reddy Devasani et al.
Antibody research has advanced through the integration of in vivo, in vitro, and in silico models, each offering distinct advantages and limitations. In vivo models, such as traditional animal models and humanized mouse models, provide crit...